Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HG381 Monotherapy in Advanced Solid Tumors
NCT04998422Phase 1Recruiting
- Sponsor
- HitGen
- Start
- Oct 2021
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HG381 in solid tumor (2 cohorts), sponsored by HitGen. Primary endpoints: Dose-Limiting Toxicity, Maximum Tolerated Dose up to 12 months and 2 more. Started Oct 2021; status: recruiting.
02
Drugs
HG381
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04998422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04998422.